Clinical Trial Update: Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the oral JAK1 inhibitor golidocitinib in newly diagnosed Peripheral T-cell lymphoma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Golidocitinib (golidocitinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING